Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib in Advanced Soft Tissue Sarcoma
NCT01140737Phase 2Completed
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Start
- Aug 2010
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axitinib in soft tissue sarcoma (STS), angiosarcoma, synovial sarcoma (SS) and 1 more, sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. Primary endpoint: Progression-free survival rate at 12 weeks. Started Aug 2010; status: completed.
02
Drugs
axitinib
03
Conditions
soft tissue sarcoma (STS)angiosarcomasynovial sarcoma (SS)leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT01140737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01140737.